Table 2. Most common recurrent copy number alterations detected by a-CGH in CDC73-mutated parathyroid tumors (T2–T8) with corresponding region of LOH.

Cytoband	Start Clone	End Clone	Position (Mb)	Size (Mb)	No. Of Clones	Freq %	Tumors Affected	SNP-based LOH	Examples*
Losses
1p21.2-13.3	RP11-721B18	RP11-483I13	102740298-108610118	5.9	75	38%	T6, T7, T5b	No	RNPC3, VAV3
9p23-24.1	RP11-403H13	RP11-382H24	6858099-13122077	6.2	73	25%	T4, T5b	No	PTPRD
18q22.1-22.2	RP11-26L13	RP11-49H23	63370817-65089302	1.7	22	25%	T6, T7	Yes	TXNDC10
Gains
1q21.3-23.1	RP11-744J16	RP11-711O18	150155440-153665553	3.5	43	25%	T6, T8	Yes	S100A5
1q32.1	RP11-115O14	RP11-161C18	196402802-203224723	6.8	88	25%	T6, T5B	Yes	ELK4
5q31.1	RP11-21C10	RP11-158M10	133880078- 135502898	1.6	24	25%	T6, T7	Yes	CAMLG, DDX46, CATSPER3, PITX1, TIFAB
9p13.1-21.1	RP11-340D22	RP13-198D9	32618776-38734139	6	74	25%	T7, T5b	No	FANCG, PAX5
11q12.2-13.2	RP11-727C13	RP11-428E19	60661723-67118617	6.5	82	25%	T8, T5b	No	MEN1
12q13.11-14.1	RP11-204C20	RP11-571M6	46894554- 56496966	9.6	138	25%	T8, T5b	No	CDK4, DDIT3 , HOXC11 and 13, NACA
16q22.1	RP11-1150F18	RP11-6M2	64948284- 69264998	4.3	61	63%	T3, T5a, T5b, T6, T8	No	CBFB, CDH1
16p11.2	RP11-544O7	RP11-466D2	27824814- 31535714	3.7	49	63%	T3, T5a, T5b, T6, T8	No	FUS
17p11.2	RP11-537F12	RP11-34O10	16592363- 18318880	1.7	21	50%	T3, T5a, T5b, T8	No	FLCN, MED9, MIR33B
18p11.21	RP11-44O1	RP11-510L15	12610439- 13384576	0.8	11	25%	T7, T8	No	PTPN2
20q11.21	RP11-802B20	RP11-471K3	29454263-31300949	1.8	21	63%	T5a, T5b, T6, T7, T8	No	ASXL1
21q22.3	RP11-1007O14	RP11-726J13	44825264- 45558273	0.7	10	38%	T3, T5a, T5b	No	PTTG1IP,
22q11.23	RP11-164N13	RP11-698L6	21892457-22518106	0.6	4	38%	T2, T5a, T5b	No	SMARCB1, BCR
22q13.1	RP11-555L22	RP11-168F23	36717836- 37293012	0.6	4	63%	T5a, T5b, T6, T7, T8	No	DDX17, DMC1

^*Genes written in bold are known cancer genes according to Cancer Gene Census, Welcome Trust, Sanger Institute.